For more than 40 years, Tom Fogarty has played a central role in global medical device innovation. Following a fruitful relationship with Edwards, which saw the development of the Fogarty embolectomy catheter and artficial heart valve, Fogarty went on to launch his own companies, including General Surgical, CTS, and Biopsys, to name just a few. In this interview, taken from a lecture series at Stanford University, Fogarty talks about his early days as a device innovator and how medical device innovation has changed today.
by David Cassak
The archetypal physician entrepreneur, Thomas Fogarty, MD, has been a driving force in medical device innovation for nearly 40 years....
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
